Nephros Inc. (NASDAQ:NEPH) Sees Large Growth in Short Interest

Nephros Inc. (NASDAQ:NEPH) was the recipient of a large growth in short interest during the month of September. As of September 15th, there was short interest totaling 16,500 shares, a growth of 323.1% from the August 31st total of 3,900 shares. Currently, 0.2% of the company’s stock are short sold. Based on an average daily volume of 48,000 shares, the days-to-cover ratio is currently 0.3 days. Based on an average daily volume of 48,000 shares, the days-to-cover ratio is currently 0.3 days. Currently, 0.2% of the company’s stock are short sold.

Hedge Funds Weigh In On Nephros

A hedge fund recently raised its stake in Nephros stock. Geode Capital Management LLC lifted its position in shares of Nephros Inc. (NASDAQ:NEPH) by 3.2% during the second quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The firm owned 93,187 shares of the company’s stock after purchasing an additional 2,898 shares during the period. Geode Capital Management LLC owned 0.88% of Nephros worth $381,000 as of its most recent filing with the Securities and Exchange Commission. 41.10% of the stock is currently owned by institutional investors.

Nephros Stock Up 2.8%

NEPH opened at $4.77 on Friday. The stock has a market cap of $50.56 million, a price-to-earnings ratio of 39.75 and a beta of 1.32. Nephros has a 12-month low of $1.36 and a 12-month high of $5.00. The business has a 50 day moving average of $4.05 and a 200-day moving average of $3.20.

Nephros (NASDAQ:NEPH) last announced its earnings results on Thursday, August 7th. The company reported $0.02 earnings per share for the quarter, topping analysts’ consensus estimates of ($0.02) by $0.04. The company had revenue of $4.40 million for the quarter, compared to analyst estimates of $3.60 million. Nephros had a return on equity of 14.89% and a net margin of 7.95%.

Wall Street Analyst Weigh In

Several research analysts have weighed in on NEPH shares. Maxim Group boosted their price target on Nephros from $4.50 to $6.00 and gave the stock a “buy” rating in a research report on Friday, August 8th. Weiss Ratings reaffirmed a “hold (c)” rating on shares of Nephros in a research report on Saturday, September 27th. Two research analysts have rated the stock with a Buy rating and one has given a Hold rating to the stock. According to MarketBeat.com, the stock presently has an average rating of “Moderate Buy” and a consensus target price of $5.50.

About Nephros

Nephros, Inc, a commercial-stage company, develops and sells water solutions to the medical and commercial markets in the United States. It offers ultrafiltration products that are used in dialysis centers for the removal of biological contaminants from water and bicarbonate concentrate; and in hospitals for the prevention of infection from waterborne pathogens, such as legionella and pseudomonas, as well as in military and outdoor recreation, commercial, and other healthcare facilities.